MorphoSys Announces Change in Executive Management Board
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces Change in Executive Management Board
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
Jens Holstein to succeed Dave Lemus as Chief Financial Officer
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that
Jens Holstein, currently Regional CFO for the region EME (Europe/Middle East) of
Fresenius Kabi AG and Managing Director of Fresenius Kabi Deutschland GmbH, will
succeed Dave Lemus both as Chief Financial Officer of MorphoSys AG and as a
member of the executive management board (Vorstand). Mr. Lemus will step down
from his position as CFO with the Company in March 2011 to pursue other
opportunities. Mr. Holstein will take up his position on May 1, 2011.
Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG, commented:
"On behalf of both the Supervisory Board and the Executive Management Board, I
would like to express my heartfelt thanks to Dave Lemus for his commitment to
helping build MorphoSys over the past thirteen years. His contributions have
been central in making the Company as successful as it is today. We wish him all
the very best for the future."
Dave Lemus has been Chief Financial Officer of MorphoSys AG since February
1998. After taking the Company public in 1999, Mr. Lemus held responsibility for
a variety of areas including corporate development, corporate communications and
legal.
"It's been a privilege to have accompanied MorphoSys's rise over the last
decade, and to participate in its development into one of Europe's leading life
science companies," commented Dave Lemus. "I leave a Company on a sound footing,
both operationally and financially, and I remain very optimistic about
MorphoSys's future prospects."
Dr. Möller continued: "We are delighted to be able to welcome an outstanding
successor in Jens Holstein, who will be a key member of the executive management
board of MorphoSys. Mr. Holstein has an exceptional track record and brings
international business experience, which will be important for the Company as it
continues its growth as one of Europe's leading biopharmaceutical companies."
Jens Holstein has served in a variety of financial and general management
positions at Fresenius since joining in 1995. From 2006 until 2010, he was
Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in
Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of
Fresenius ProServe GmbH and Finance Director and Labor Director of the company's
subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius
included General Manager of hospitalia care GmbH, Commercial Manager of the
Projects & Service business unit of Fresenius AG and Commercial Manager of
hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent
six years in the consulting industry, with positions in Frankfurt and London.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys; arYla(TM) is a trademark of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release:
http://hugin.info/130295/R/1491878/427596.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1491878]
Unternehmensinformation / Kurzprofil:
Datum: 24.02.2011 - 07:01 Uhr
Sprache: Deutsch
News-ID 51844
Anzahl Zeichen: 7350
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Change in Executive Management Board"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
